Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).
1 finding from 1 review
- RR 0.98 [0.72, 1.33]2 studies · 1096 participantsModerate